| 37.11 -0.82 (-2.16%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 51.79 | 1-year : | 57.29 |
| Resists | First : | 44.34 | Second : | 49.04 |
| Pivot price | 40.56  |
|||
| Supports | First : | 36.72 | Second : | 30.55 |
| MAs | MA(5) : | 38.19 |
MA(20) : | 42.16 |
| MA(100) : | 53.59 |
MA(250) : | 58.35 |
|
| MACD | MACD : | -2.4 |
Signal : | -2.1 |
| %K %D | K(14,3) : | 7.2 |
D(3) : | 6.9  |
| RSI | RSI(14): 27.2 |
|||
| 52-week | High : | 71.84 | Low : | 36.72 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NARI ] has closed above bottom band by 8.4%. Bollinger Bands are 11.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 38.61 - 38.98 | 38.98 - 39.21 |
| Low: | 36.03 - 36.51 | 36.51 - 36.8 |
| Close: | 36.56 - 37.34 | 37.34 - 37.81 |
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Mon, 22 Apr 2024
Inari Medical (NASDAQ:NARI) Reaches New 52-Week Low at $36.73 - MarketBeat
Fri, 19 Apr 2024
Lowey Dannenberg, P.C. is Investigating Inari Medical Inc. - GlobeNewswire
Thu, 18 Apr 2024
Insider Selling: Inari Medical, Inc. (NASDAQ:NARI) Director Sells 1,451 Shares of Stock - MarketBeat
Thu, 18 Apr 2024
Inari Medical, Inc. (NARI) Downgraded by Analysts Due to Pending DOJ Probe – Hagens Berman - GlobeNewswire
Wed, 17 Apr 2024
Inari Medical to Announce First Quarter 2024 Financial Results - GlobeNewswire
Tue, 09 Apr 2024
Why You Should Retain Inari Medical (NARI) Stock for Now - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 58 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 9.5 (%) |
| Held by Institutions | 93.1 (%) |
| Shares Short | 3,990 (K) |
| Shares Short P.Month | 5,050 (K) |
| EPS | -0.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.05 |
| Profit Margin | -0.4 % |
| Operating Margin | 0.8 % |
| Return on Assets (ttm) | -0.4 % |
| Return on Equity (ttm) | -0.4 % |
| Qtrly Rev. Growth | 22.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 8.51 |
| EBITDA (p.s.) | 0.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 36 (M) |
| Levered Free Cash Flow | 39 (M) |
| PE Ratio | -1237 |
| PEG Ratio | -1.2 |
| Price to Book value | 4.6 |
| Price to Sales | 4.35 |
| Price to Cash Flow | 59.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|